CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Citi puts Australia's Telix on positive catalyst watch of Zircaix FDA filing

By Reuters News17 hours ago Updated

** Citi opens a 90-day positive catalyst watch on Telix Pharmaceuticals TLX.AX, citing an expected resubmission of kidney cancer imaging agent Zircaix to the US FDA by year-end

** Brokerage says intact FY26 guidance and a good start to the quarter imply modest Q4 growth in Prostate-Specific Membrane Antigen sales for the biopharma firm

** Citi estimates low single-digit net pricing decline as accounts won have greater exposure to more heavily discounted channels

** Brokerage adds TLX's newly launched imaging drug for brain cancer, Pixclara, has an early average selling price of $8,900 per dose, which is higher than expected

** Citi retains TLX's price target of A$31 on ASX-listed shares

** YTD, stock up 14.7%, as of last close

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.